Corcept Therapeutics | CORT - Interest Expense On Debt

Stock Price
40.78
Daily Change
0.91 2.28%
Monthly
16.68%
Yearly
-38.72%
Q1 Forecast
38.64

Corcept Therapeutics reported $823.61M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alaunos Therapeutics USD 0 0 Dec/2023
ANI Pharmaceuticals USD 4.73M 711K Sep/2025
Ardelyx USD 5.8M 784K Sep/2025
Aurora Cannabis CAD 2.22M 442K Sep/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Canopy Growth CAD 8.8M 938K Sep/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
J&J USD 18M 290M Sep/2025
Knight Therapeutics CAD 2.37M 6K Sep/2025
Merck USD 327M 22M Sep/2025
Novartis USD 281M 8M Sep/2025
Novartis USD 281M 8M Sep/2025
Pacira USD 4.28M 456K Sep/2025
Pfizer USD 652M 2M Sep/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
TG Therapeutics USD 6.72M 4K Sep/2025